| |

New Tool Measures Stress Levels Among Mesothelioma Caregivers

mesothelioma caregiversPreliminary tests of a new tool designed to measure stress levels among mesothelioma caregivers shows that the tool is both reliable and helpful. 

The tool was developed by occupational medicine researchers in Rome. Their goal was to create a “short, flexible, and comprehensive tool” to detect psychological distress in carers. 

The team recently tested the tool in a group of mesothelioma caregivers. Their results have just been published in the journal Psycho-Oncology. 

The Strain of Caring for a Loved One with Mesothelioma

Malignant mesothelioma is a highly lethal type of membrane cancer. Most mesothelioma patients lived or worked around asbestos. 

Pleural mesothelioma is the most common type of mesothelioma. It affects about 2,000 people in the US every year. Another 500 people receive a diagnosis of peritoneal mesothelioma. 

Both patients and mesothelioma caregivers face stress and uncertainty as the disease progresses. Three is no cure and standard treatments are only moderately effective. 

People with pleural mesothelioma gradually lose their ability to breathe freely. They may develop a cough and chest pain as tumors grow around their lungs. Patients with peritoneal mesothelioma can have gastrointestinal symptoms. They may have abdominal pain and trouble with digestion. Both types of mesothelioma are usually fatal within a year. 

“Taking care of malignant mesothelioma patients is a stressful process that influences the caregiver’s physical, emotional, and social wellbeing,” writes researcher Michela Bonafede. Dr. Bonafede works for the Italian Workers’ Compensation Authority. 

Mesothelioma Caregivers Need Support, Too

A number of studies show high levels of distress among mesothelioma patients and the people who take care of them. 

It is always painful to watch a loved one decline. The fact that mesothelioma is so rare can make the experience even more isolating. There may be no other mesothelioma caregivers in the local support group. In addition, the lack of good treatment options can lead to feelings of hopelessness. 

But the mental wellbeing of mesothelioma caregivers impacts patients. When caregivers feel supported and understood, they are better able to support their loved ones through treatment and beyond. That is the idea behind the Mesothelioma Psychological Distress Tool-Caregivers version (MPDT-C).

Developers started by reviewing the medical literature for studies on stressors among mesothelioma caregivers. They developed a 47-item questionnaire based on three major stress areas: Secondary Traumatic Stress, Engagement in Caring, and Meaningful Cognitive Restructuring. 

They tested the tool in multiple Italian medical centers. The results show the tool is a good reflection of carer distress. 

“Results suggest that the MPDT-C is a reliable tool with which to detect the psychological distress of this traumatized population,” writes Dr. Bonafede. “Our study offers preliminary evidence in support of the adequate psychometric properties of the MPDT-C, and these should now be replicated.” 

Source: 

Bonafede, M, et al, “Preliminary validation of a questionnaire assessing psychological distress in caregivers of patients with malignant mesothelioma: Mesothelioma Psychological Distress Tool-Caregivers”, August 18, 2021, Psycho-Oncology, Online ahead of print, https://onlinelibrary.wiley.com/doi/10.1002/pon.5789

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…